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Abstract
Considering the many secondary natural metabolites available from plants, phenolic compounds play a particularly important role
in human health as they occur in significant amounts in many fruits, vegetables and medicinal plants. In this review natural phenolic
compounds of plant origin with significant anti-angiogenic properties are discussed. Thirteen representatives from eight different
natural or natural-like phenolic subclasses are presented with an emphasis on their synthesis and methods to modify the parent com-
pounds. When available, the consequence of structural variation on the pharmacological activity of the molecules is described.
Introduction
The term angiogenesis is commonly used to describe the bio-
logical process of blood vessel growth. Nevertheless, it should
be more precisely defined as the formation of new blood vessels
from preexisting ones. Under physiological conditions, angio-
genesis is vital for foetal development, tissue regeneration and
wound healing. From a pathophysiologic perspective, massive
vascular growth or abnormal shape formation promotes many
ailments including cancer, inflammation, and eye illnesses.
Additionally, inadequate vessel preservation or growth leads to
ischemia causing myocardial infarction, stroke, and neurode-
generative or obesity-associated conditions [1,2].
The generation of new blood vessels is based on a strictly
controlled balance between various soluble and membrane-
bound factors showing either anti- or pro-angiogenic activity,
which are embedded together with enzymes and signaling mole-
cules (Table 1) into a very complex network of signaling path-
ways [3,4]. For example, in the case of cancer development, the
growing tumor disturbs the angiogenic balance in tissue and
induces the secretion of pro-angiogenic factors either by the
tumor cells themselves or by cells of the tumor microenviron-
ment. After the tumor reaches a diameter of 1–2 mm, the tumor
cells located far away from blood vessels undergo apoptosis or
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Table 1: Brief overview of the endogenous modulators involved in angiogenic processes.
Group name Modulators (abbreviation)
Growth factors Vascular endothelial growth factor (VEGF)
Fibroblast growth factor (FGF)
Platelet-derived growth factor (PDGF)




Proteinases Matrix metalloproteinases (MMPs)
Urokinase plasminogen activator (uPA)
Extracellular matrix proteins Fibronectin
Collagens
Transcription factors Nuclear factor (erythroid-derived 2)-related factor (Nrf2)
Nuclear factor “kappa-light-chain-enhancer” of activated B-cells (NF-κB)
Activator protein (AP-1)
Hypoxia inducible factor (HIF)
Other signaling molecules Mammalian target of rapamycin (mTOR)
Other enzymes Mitogen-activated protein kinases (MAP-kinases)
Proteinkinases A and C (PKA and PKC)
Proteinkinase BAkt
Cyclooxygenase 2 (COX-2)
Nitric oxide synthase (NOS)
necrosis resulting from the lack of oxygen and nutrients. At that
point, the tumor cells express pro-angiogenic factors including
growth factors such as the vascular endothelial growth factor
(VEGF) and fibroblast growth factor (FGF) and enzymes such
as cyclooxygenase 2 (COX-2) and protein kinase A (PKA) as
well as signaling molecules such as integrins. The evoked
cascade effect subsequently induces the formation of new blood
vessels that quickly connect to preexisting blood vessels, thus
providing a sufficient supply of nutrients for tumor survival [5].
In addition, the new blood vessels allow the cancer cells to
spread from a parent location to other areas causing metastases.
Nevertheless, the morphology and pathophysiology of these
blood vessels differs significantly from physiological ones as
they are less effective and show a lower state of organization
and control [3]. Since the discovery of the mechanism of angio-
genesis and its crucial role in tumor development, various thera-
pies targeted at interfering with this process were investigated
[6]. The favored clinical targets are the VEGF receptors, which
have led to the development and approval of monoclonal anti-
bodies against VEGF and VEGF receptor tyrosine kinase
inhibitors [3]. However, the existing therapy options with anti-
bodies and VEGF receptor inhibitors showed several clinical
limitations, making the search for further clinically relevant
targets and other drugs necessary to combat tumor-related
angiogenesis.
Secondary natural metabolites have also been identified as
attractive candidates for the therapy of pathologically-induced
angiogenesis [7,8]. Among such natural products, phenolic or
polyphenolic compounds with anti-angiogenic properties have
been investigated and the opinion regarding their potential phar-
macological impact has changed over the years. While the phar-
macological activity of polyphenols was previously considered
as unspecific, more recently, observations of a specific interfer-
ence with biological mechanisms at the molecular level have
significantly increased. Especially in the fields of anti-inflam-
matory activity, chemoprevention and cytoprotection, natural
phenolic metabolites such as flavonoids, caffeic acid deriva-
tives and diarylheptanoids were found to have a pleiotropic
influence on cellular signaling (e.g., by the inhibition of tran-
scription factors such as NF-κB or Nrf2 [9,10], or antioxidative
effects [10,11]). Furthermore, polyphenols are found in high
concentrations in many fruits and vegetables, resulting in a
continuous and long-term intake of such plant phenols. Conse-
quently, their beneficial and protective impact on unbalanced
angiogenic processes has been intensively discussed [7,8].
In the last decade, many excellent review articles summarized
the biological and pharmacological aspects of anti-angiogenic
compounds, including natural compounds containing a phenolic
substructure [12-14]. To complement this previously discussed
pharmacological point of view, this review focuses on recent
reports of anti-angiogenic, natural, phenolic compounds, specif-
ically addressing their chemistry, synthesis and possible struc-
ture modifications. Nevertheless, it should be mentioned that
the selection of compounds for this review is based on the
reports of their pharmacological activity. As the term “anti-
angiogenic compound” is not clearly defined and somewhat
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Table 2: In vitro, ex vivo and in vivo assays used to evaluate anti-angiogenic activity.a
In vitro assays Assay principles/Detection, read out
Endothelial cell proliferation assays Cell counting/Increase of cell number
Crystal violet/Increase of cell number
MTT/Activity of dehydrogenase activity (positively correlated to cell number)
Incorporation of [3H]thymidine, 5-bromodeoxyuridine into DNA/DNA synthesis
(positively correlated to cell number)
Endothelial cell migration assays Scratch assay/Migration into a denuded area (wound healing)
Endothelial cell differentiation assays Tube formation, e.g., in Matrigel/Formation of capillary-like tubules
Endothelial-mural cell co-culture assays Interaction between two cell types (endothelial/mural)/Influence on cell
differentiation and proliferation
Ex vivo assays
Aortic ring assay Aorta of rodents cultured in biological matrices/Outgrowth of branching
microvessels
In vivo assays
Chick chorioallantoic membrane assay (CAM) Extra-embryonic membrane (in ovo, ex ovo)/Growth and branching of blood
vessels
Hen's egg test on chorioallantoic membrane
(HETCAM)
CAM modification/Growth and branching of blood vessels
Zebrafish Zebrafish embryos or transgenic zebrafish embryos/Visualization of
vascularisation (e.g., with confocal microscopy)
Corneal angiogenesis assay Corneal injury or implantation of pellets/Vascular response of the cornea
Dorsal air sac model Ring (filled with tumor cell suspension) implantation (dorsal
skin)/Tumor-induced angiogenesis
Mouse models Genetically engineered mouse models/Xenografts
aMolecular or enzyme assays are not included.
overly used, it was necessary to unequivocally define this term
for this review. The compounds included in the survey were
those shown to exhibit anti-angiogenic activity not only in con-
venient (and often descriptive) cellular in vitro assays (Table 2),
but also in molecular in vitro test systems related to the
signaling cascades of pathological angiogenesis. Further crite-
rion for inclusion in this survey was the presence of anti-angio-
genic activity obtained in ex vivo and in vivo assays (Table 2).
Additionally, the observed in vitro activity should be in the
lower µM range (or higher), which is high enough to realisti-
cally speculate on the anti-angiogenic activity in vivo. As
endothelial cells (ECs) have particular significance in angiogen-
esis, results from cellular assays using primary or immortalized
ECs such as human umbilical vein endothelial cells (HUVEC)
or human microvascular endothelial cells (HMEC-1) have been
given special attention. In contrast, compounds showing in vitro
anti-angiogenic activity but also signs of strong unspecific cyto-
toxic effects in vitro have been excluded. The secondary
metabolites discussed include six flavonoids from different
subclasses: quercetin, fisetin, epigallocatechin-3-O-gallate,
xanthohumol, (2S)-7,2’,4’-trihydroxy-5-methoxy-8-dimethyl-
allylflavanone and genistein. Other compounds belong to the
group of simple phenols (4-hydroxybenzyl alcohol),
hydrolysable tannins (ellagic acid), stilbenoids (resveratrol) and
diarylheptanoids (curcumin). In addition, acylphloroglucinols,
quinolone-substituted phenols and 4-amino-2-sulfanylphenol
derivatives are discussed. Some important aspects of the
described pharmacological activities of the compounds are
summarized in Table 3.
Review
4-Hydroxybenzyl alcohol
4-Hydroxybenzyl alcohol (HBA, 1) (Figure 1) is a well-known
phenolic compound found in plants and has been isolated from,
for example, the flowers of carrot (Daucus carrota L.,
Apiaceae). In 2007, Park and co-workers [15] found no change
in the vascular density in the chick chorioallantoic membrane
(CAM) assay in the presence of HBA, indicating that HBA had
no influence on the growth of the blood vessels. In contrast, the
branching pattern of the blood vessels was dose-dependently
reduced in the same assay, implying that an inhibition of angio-
genesis was plausible. Later, Laschke et al. [16] performed
experiments in vitro with an aortic ring assay and in vivo in an
endometriosis model as well as the systematic analysis of the
mechanism underlying the anti-angiogenic activity of HBA.
They found that HBA is capable of inhibiting several steps in
Beilstein J. Org. Chem. 2015, 11, 249–264.
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Table 3: Natural phenolic compounds with anti-angiogenic activity and their evaluated molecular mechanisms of anti-angiogenesis.
Compound name Mechanisms of anti-angiogenic action
4-Hydroxybenzyl alcohol Downregulation of VEGF and MMP9 protein expression
Curcumin Reduction of VEGF expression, inhibition of transcription factors, mTOR
pathway and MMP9 protein expression
Ellagic acid Inhibition of VEGF and PDGF receptor phosphorylation
Resveratrol Abrogation of VEGF-mediated tyrosine phosphorylation of vascular
endothelial (VE)-cadherin, inhibition of VEGF-induced and FGF-2
neovascularization
Quinoline-substituted phenols Inhibition of VEGF and Transforming Growth Factor-β1 (TGF-β1) expression
4-Amino-2-sulfanylphenol derivatives Inhibition of protein kinase B/Akt and ABL tyrosine kinase
Natural-like acylphloroglucinol derivatives Under investigation
(−)-Epigallocatechin gallate (EGCG) Inhibition of estrogen-stimulated VEGF expression, HIF-1α and NF-κB,
inhibition of MMP-2 and MMP-9, inhibition of urokinase plasminogen
activator.
Xanthohumol Inhibition of NF-κB and Akt pathways
Genistein Inhibition of VEGF and HIF-1α protein expression
Fisetin Downregulation of VEGF and eNOS expression, inhibition of MMPs activities
Quercetin Inhibition of the expression of VEGF-2, inhibition of COX-2 and arachidonate




Downregulation of reactive oxygen species (ROS) levels and VEGF
expression
the angiogenic mechanism. Western blot analysis showed the
downregulation of VEGF and MMP9 protein expression. The
effect of HBA was confirmed [17] by mouse dorsal skinfold
chamber experiments. The incubation of CT26.WT colon carci-
noma cells with HBA showed a dose-dependent decrease in
their viability and integrity. In addition, the cell expression of
the apoptosis marker, cleaved caspase-3, significantly increased
and the expression of vascular endothelial growth factor
(VEGF) and matrix metalloproteinase (MMP)-9 decreased
compared to the controls. No influence on the normal behavior
of the animals was observed. In general, HBA represents an
interesting anti-angiogenic agent for the treatment of angio-
genic diseases.
Figure 1: Structure of 4-hydroxybenzyl alcohol (HBA, 1).
Curcumin
Curcumin (3) is a natural product isolated from different
Curcuma species (Zingiberaceae) some of which are used as
raw material in the spice turmeric. It has been evaluated as a
chemopreventive agent since the early nineties, and in 1998,
Arbiser and co-workers [18] found that the compound also
demonstrated anti-angiogenic properties in in vitro and in vivo
experiments. In the following years, many studies on the anti-
angiogenic properties in different tumor cell lines and in animal
models were reported [19-22]. They included interactions with
the transcription factor NF-κB, mTOR pathway, and reduction
of VEGFA and MMP9 expression. Despite its promising phar-
macological properties, curcumin suffers from low in vivo
bioavailability as a consequence of its low aqueous solubility,
poor chemical stability and low absorption. Therefore, many
analogs (Figure 2) were synthesized in order to overcome these
drawbacks and to enhance the activity. In addition, their struc-
ture–activity relationships were studied to gain better insight
into the mode of action. The general synthesis of curcumin
itself (Scheme 1) [23,24] requires masking of the reactive meth-
ylene group of the acetylacetone moiety by formation of a com-
plex with boric oxide, followed by reaction with vanillin.
Instead of boric oxide, alkyl borates and boric acid can also be
used. The first attempt at modification was to truncate the
general structure to either a single enone or dienone system.
The latter structure contained a diarylpentanoid moiety instead
of the natural diarylheptanoid backbone. In some cases, this was
amended by a central ring system and was labeled as monocar-
bonyl analog of curcumin (MACs, Figure 3). Bowen et al. [25]
used the Claisen–Schmidt reaction for the synthesis of these
analogs. The C7-chain linker between the two aromatic rings
was shortened, and a series of compounds (Scheme 2) with
different substitutions on the aromatic rings was synthesized to
explore the role of stereoelectronic effects. It was demonstrated
that these analogs of curcumin showed excellent anti-angio-
Beilstein J. Org. Chem. 2015, 11, 249–264.
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Figure 2: Structure–activity relationship of curcumin analogs.
Scheme 1: Synthesis of curcumin (3). Reagents and conditions: (a) vanillin, 1,2,3,4-tetrahydroquinoline, HOAc, H3BO3, DMF, Δ, 4 h.
Scheme 2: Exemplary synthesis of MAC representatives. Reagents and conditions: (a) 40% KOH, EtOH, 5 °C; stirring 10 h, rt. X = C, N; R = OH,
OMe, Cl, F.
Figure 3: Backbone and substitution of monocarbonyl analogs of
curcumin (MACs) showing their structural diversity.
genic activity with equivalent or superior inhibition to that of
the natural parent product. This work was followed by more
comprehensive bioactive studies on aromatic enones utilizing
the substituted chalcone backbone [26]. The study showed that
the presence of the enone moiety played an important role in
maintaining the activity in the curcumin analogs. Using this
principle, Ahn et al. (2005) [27] left the enone unchanged and
prepared various curcumin mimics with asymmetric units
bearing alkyl amide, chloro-substituted benzamide, or
heteroaromatic amide moieties. These analogs exhibited a
stronger anti-angiogenic activity against HUVECs than
curcumin. To date, the number of synthesized single enones and
MACs have surpassed the 1000 mark.
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Scheme 3: Synthesis of ellagic acid (7). Reagents and conditions: (a) H2SO4, CH3OH; (b) (1) o-chloranil, Et2O, −40 °C; −40 °C → rt, 3 h;
(2) Na2S2O4, rt, 30 min; (c) MeOH/H2O 1:1, reflux.
Figure 4: Structure of resveratrol and its analogs.
Ellagic acid
Ellagic acid (7) is a naturally existing phenolic antioxidant
widely found in numerous fruits and vegetables, such as rasp-
berries (Rubus idaeus L., Rosaceae), strawberries (Fragaria
spec. L., Rosaceae) and pomegranates (Punica granatum L.,
Lythraceae). It shows potent antioxidant effects by radical scav-
enging and the inhibition of lipid peroxidation [28,29]. Ellagic
acid is also capable of interfering with some angiogenesis-
dependent pathways. It exhibits anticarcinogenic activity
through inhibiting of tumor-cell proliferation, migration and
induction of apoptosis. In addition, it is a dual inhibitor of the
phosphorylation of VEGF and PDGF receptors, thus inter-
rupting the angiogenetic processes required for tumor growth
[30]. Recently, it was reported that its anti-angiogenesis mecha-
nism affects the VEGFR-2 signaling pathway by forming
hydrogen bonds and aromatic interactions within the ATP-
binding region of the VEGFR-2 kinase unit [31]. Shankar and
Srivastava et al. [32] treated PANC-1 xenograft mice with
ellagic acid (7) and measured the expression of protein kinase B
(Akt), sonic hedgehog (Shh) and Notch. The results suggested
that ellagic acid effectively inhibited human pancreatic cancer
growth by suppressing the Akt, Shh and Notch pathways. The
preparation of ellagic acid (7) can be achieved by the oxidative
coupling of gallic acid (Scheme 3) [33]. In the presence of
H2SO4, gallic acid (4) was esterified to methyl gallate (5). The
obtained ester 5 was first oxidatively coupled in the presence of
o-chloranil, followed by reduction with Na2S2O4 to obtain the
hexahydroxy biphenyl 6. Subsequent lactonization afforded the
final product, ellagic acid (7), in high yield.
Resveratrol
Resveratrol (8) is a natural polyphenol that belongs to the stil-
bene-type compounds and exists in a large number of plants. It
has been primarily extracted from grape (Vitis vinifera L.,
Vitaceae) and mulberry (Morus L., Moraceae) fruits (Figure 4)
[34]. It has antioxidant effects, anti-estrogenic activity and the
ability to reduce the synthesis of hepatic lipids and of
eicosanoids. It inhibits platelet aggregation and protects vessels
from arteriosclerosis [34-38]. In recent years, it has been
reported that resveratrol is sufficiently potent to inhibit VEGF-
induced and FGF-2 neovascularization in vivo [39]. It was also
shown that resveratrol directly inhibited bovine aorta endothe-
Beilstein J. Org. Chem. 2015, 11, 249–264.
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Scheme 4: Synthesis of quinolone-substituted phenol 20. Reagents and conditions: (a) Ac2O, 2-hydroxybenzaldehyde, 130 °C; (b) (1) Br2, AcOH,
(2) Ac2O; (c) (1) DBU, THF, (2) Ac2O; (d) Na2CO3, MeOH/THF.
Scheme 5: Synthesis of quinolone-substituted phenol 23. Reagents and conditions: (a) Ac2O, 2-hydroxybenzaldehyde; (b) (1) NaOH, EtOH/H2O,
100 °C, (2) HCl.
lial cell proliferation, migration and tube formation in vitro
[40]. Resveratrol has also been found to effectively interrupt
VEGF-mediated tyrosine phosphorylation of vascular endothe-
lial (VE)-cadherin and its complex partner, β-catenin [41].
Unfortunately, resveratrol has a dual effect on cells, depending
on the situation and cell type – it can either induce or suppress
angiogenic effects [42]. The low oral bioavailability and meta-
bolic stability of resveratrol also limits its application [43].
Therefore, in an attempt to increase its bioavailability and
stability, the structure of resveratrol was modified by methyl-
ation of the phenol groups [44] and by introduction of other
groups on the phenyl ring (compounds 9–15, Figure 4) [45].
trans-3,4,4’,5-Tetramethoxystilbene (DMU-212) has improved
pharmacokinetic properties as compared to resveratrol and
shows antiproliferation activity in various cancer cells [46-48].
The further investigation of its role in angiogenesis by Dai and
Zhang et al. [49] showed that DMU-212, a potential anti-angio-
genic agent, inhibits VEGFR2 phosphorylation and thereby acts
to suppress the signaling pathways mediated by VEGFR2,
inducing apoptosis in endothelial cells.
Quinoline-substituted phenols
To date, quinolone-substituted phenols (Qsps) have not been
reported as natural secondary metabolites, although quinolone
and alkylated phenols are common structural elements of sec-
ondary plant products. The quinoline skeleton is present in alka-
loids derived from tryptophane-like quinine or camptothecine,
whereas alkylated phenols with a varying alkyl side chain
length are common metabolites from the shikimate pathway.
Qsps were reported in a recent patent [50] to be effective for the
treatment of angiogenesis-related diseases or disorders. Among
other assays, a transgenic line of zebrafish that expresses a fluo-
rescent reporter (EGFP) in vasculature was used in this study to
identify anti-angiogenic compounds. Special emphasis was
placed on the integrity of the vessels developing in the eyes and
in the trunk. Quinoline-substituted phenols were identified as
being active based on a significant inhibition of the hyaloid
vessel formation in the zebrafish model. The synthesis of two
representative compounds, 20 and 23, of this class are shown in
Scheme 4 and Scheme 5, respectively [50].
After condensation of 16 with hydroxybenzaldehyde, product
17 was subsequently brominated, followed by twofold elimina-
tion of HBr forming the triple bond. Finally, ester hydrolysis
provided compound 20. Compound 23 was obtained from an
analogous condensation product, 22, by hydrolysis under basic
condition.
4-Amino-2-sulfanylphenol derivatives
The class of 4-amino-2-sulfanylphenols is obviously an outlier
among the reviewed compounds, as the 2-sulfanylphenol
substructure is not a structural element in natural products. The
vast majority of thiol groups in secondary metabolites derive
from the amino acid cysteine, producing aliphatic secondary
Beilstein J. Org. Chem. 2015, 11, 249–264.
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Figure 5: Design of 4-amino-2-sulfanylphenol derivatives and their structure–activity relationship.
Scheme 6: Synthesis of 4-amino-2-sulfanylphenol derivatives. Reagents and conditions: (a) R1SO2Cl, pyridine, 0 °C; (b) NaIO4/SiO2, DCM; (c) DMF,
R2SH.
metabolites with thiol functionalities instead of phenolic ones.
Nevertheless, this class contains thio-analogs of the naturally
occurring o-catechol substructure, and thus, it has been included
in this review. Zhang and Xu et al. [51] have reported that
4-amino-2-sulfanylphenol derivatives display highly specific
protein kinase and angiogenesis inhibitory activities. Based on
their previous findings, the structure of compound 24 was opti-
mized by replacing the naphthalene by a phenolic skeleton and
a sulfonamide fragment [52]. These compounds show in vitro
anti-angiogenic activity with respect to Pazopanib in both
HUVEC tube formation assay and the rat thoracic aorta
ring test. They inhibited protein kinase B/Akt and ABL tyro-
sine kinase in the micromolar range. The preliminary
structure–activity relationship is summarized in Figure 5.
The synthesis of 4-amino-2-sulfanylphenol compounds
(Scheme 6) [53] starts from the 4-aminophenol hydrochloride
salt (25), which reacted with various substituted sulfonyl chlo-
rides in pyridine, yielding compound 26 that differs in the
substituent R1. Oxidation by NaIO4/SiO2 gives the quinone-
type structures 27, which were reacted without further purifica-
tion with R2SH thiols. The addition to the unsaturated system
yielded the target compound 28 with different arylthiol groups
under rearomatization.
Acylphloroglucinol derivatives
Acylphloroglucinols are typical secondary metabolites biosyn-
thetically derived from the polyketide pathway and mainly
accumulate in Hypericaceae [54] and Clusiaceae. Hyperforin,
likely the most prominent acylphloroglucinol derivative and
present in higher concentration in St. John’s wort (Hypericum
perforatum L., Hypericaceae), has been recently reported to ex-
hibit strong antiproliferative effects [55] that strongly inhibit
angiogenesis in both in vitro and in vivo models. Mechanisti-
cally, it interferes with MMP-2 and a urokinase plasminogen
activator (uPA) [56]. However, due to its instability in aqueous
Beilstein J. Org. Chem. 2015, 11, 249–264.
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Figure 6: Structures of two series of natural-like acylphloroglucinols.
Scheme 7: Synthesis of acylphloroglucinol derivatives 35–41. Reagents and conditions: (a) acyl chloride, AlCl3, CS2/PhNO2, 55 °, 2 h; (b) geranyl
bromide, K2CO3, acetone, reflux, overnight; (c) pTSA, benzene, reflux, 2 h.
solution, complex structure and limited availability, hyperforin
is neither a drug candidate nor a good model compound. The
finding that structurally simpler, natural, acylphloroglucinol
derivatives also showed antiproliferative effects against
endothelial cells with inhibitory effects in a tube-formation
assay on Matrigel catalyzed the search for simple acylphloro-
glucinols with anti-angiogenic activity. Within this group, some
geranylated monocyclic and bicyclic acylphloroglucinol deriva-
tives have been identified that are structurally much more
simple than hyperforin. However, they exhibiting potent anti-
proliferative activity for a human microvascular endothelial cell
line (HMEC-1) at low micromolar concentrations [57,58]. Two
series of natural-like acylphloroglucinols were synthesized
(Figure 6) for the systematic investigation of their anti-angio-
genic properties [59].
The compounds of the first series [59] were prepared starting
from 1,3,5-trihydroxybenzene (29, Scheme 7). Compounds
30–34 were obtained through Friedel–Crafts acylation of 29
with corresponding acyl chlorides in 55–81% yield. Subse-
quent alkylation with geranyl bromide gave products 35–39 in
moderate yields from 55 to 60%. Finally, p-toluenesulfonic acid
(pTSA)-catalyzed cyclization afforded the target compounds 40
and 41 in 53 and 65% yield, respectively.
The synthesis of the second series is shown in Scheme 8 [59].
Amberlyst 15 efficiently catalyzed the condensation of 1,3,5-
trihydroxybenzene (29) with isoprene in 53% yield. The
following Friedel–Crafts acylation gave the intermediates
43–46, which were subsequently demethylated using BBr3 to
give compounds 47–51 in 48 to 78% yield.
Compound 47 (R1 = H, R2 = OH, R3 = OH) showed antiprolif-
erative activity with an IC50 of 0.88 ± 0.08 µM in vitro. Com-
pound 38 (alkyl = CH(CH3)CH2CH3) exhibited a moderate
antiproliferative effect (IC50 = 11.0 ± 1 µM) and inhibited the
capillary-like tube formation of HMEC-1 in vitro, whereas 47
was inactive. Furthermore, some of the compounds showed
Beilstein J. Org. Chem. 2015, 11, 249–264.
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Scheme 8: Synthesis of acylphloroglucinol derivatives 43–51. Reagents and conditions: (a) isoprene, Amberlyst 15, THF/hexane; (b) benzoyl chlo-
ride, AlCl3, DCM, −5 °C to rt, overnight; (c) BBr3, DCM, −78 °C to rt, overnight.
significant antioxidative activity. The most active compound in
the ORAC assay was compound 47, which exhibited an
antioxidative effect of 6.6 ± 1.0 TE. However, this compound
showed only weak activity during the proliferation assay
(IC50 = 53.8 ± 0.3 µM) and did not inhibit tube formation.
A basic structure–activity relationship of the aliphatic mono-
and bicyclic acylphloroglucinol derivatives with short acyl side
chains indicates that the in vitro antiproliferative activity of
these acylphloroglucinols in HMEC-1 increases with increasing
log P. Increasing the number of carbon atoms in the acyl group
provides higher lipophilicity, which allows the compound to
better penetrate across cellular membranes in the in vitro assay.
In contrast, the activity of the derivatives with aromatic acyl
side chains depends on other properties. The molecular aspects
of the observed cellular effects are currently under investi-
gation.
(−)-Epigallocatechin-3-O-gallate (EGCG)
(−)-Epigallocatechin-3-O-gallate (EGCG, 52) is the most abun-
dant catechin in green tee (Camellia sinensis L. KUNZE,
Theaceae). It is the esterification product of epigallocatechin
and gallic acid. Many studies provide evidence that EGCG
modulates multiple signal transduction pathways, controlling
the unwanted proliferation of cells. It inhibits the activation of
HIF-1α, NF-κB and VEGF expression, thereby suppressing
tumor angiogenesis and cancer progression [60,61]. Further-
more, EGCG inhibited MMP-2 and MMP-9 (in different cell
types), which seem to play an important role in tumor invasion
and metastasis. Also, the inhibition of uPA by EGCG has been
observed [62]. Urokinase plasminogen activator (uPA) has the
ability to prevent apoptosis, it also stimulates angiogenesis,
mitogenesis, cell migration, as well as modulates cell adhesion.
The presence of the 3-galloyl moiety in catechins led to higher
biological activity [63-65], but an increasing number of
aromatic hydroxy groups result in low stability and the inability
of the compound to cross cellular membranes [66]. To prevent
oxidation and improve its bioavailability, modifications of
EGCG focus on synthesizing more stable analogs (Figure 7).
Anderson et al. [67] replaced the hydrolytically labile ester
bond with a more stable amine and amide bond and evaluated
their efficacy as modulators for β-lactam resistance in S. aureus.
Landis-Piwowar et al. [68] and Wang et al. [69] protected the
hydroxy groups through peracetylation. These analogs behave
as prodrugs and the acetyl group is removed by cellular
cytosolic esterases. Liao et al. [70] and Huang et al. [71]
acylated the phenol group at the 3-position, introduced fatty
acids of different sizes and extensively explored their
structure–activity relationship to 5α-reductase. Park and
co-workers [72] also synthesized 3-O-alkyl analogs of epicate-
chin. They found that the introduction of alkyl groups instead of
acyl groups enhanced the antimicrobial activity and stability at
pH 7.4.
Xanthohumol
Xanthohumol (XN, 58), a naturally occurring prenylated chal-
cone in hop plants (Humulus lupulus L., Cannabaceae), has
been suggested to have potential to suppress the development
and progression of cancer and is therefore also a compound of
chemopreventive potential [73,74]. For example, XN shows
proliferative inhibition of human breast (MCF-7), colon (HT-
29), and ovarian cancer (A-2780) cells in vitro with IC50s
ranging from 0.52 to 13.3 μM. Because most cancer chemopre-
ventive agents have also anti-angiogenic properties in vitro and
in vivo, further investigations [75] showed that XN repressed
both the NF-κB and Akt pathways in endothelial cells, inhib-
ited VEGF-A expression in a wound-healing assay, and exhib-
ited interference in the angiogenic process. The first complete
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Figure 7: Analogs of (−)-EGCG for the prevention of oxidation and improvement of the bioavailability of the compounds [67,70-72].
Scheme 9: Synthesis of xanthohumol 58. Reagents and conditions: (a) MOMCl, diisopropylethylamine, CH2Cl2; (b) 3-methyl-2-butene-1-ol, diethyl
azodicarboxylate, PPh3, toluene/THF; (c) N,N-dimethylaniline, reflux; (d) (CH3O)SO2, K2CO3, acetone, reflux; (e) 4-methoxymethylbenzaldehyde,
aqueous NaOH, MeOH, reflux; (f) concentrated HCl (pH 1), MeOH/H2O, rt.
synthesis of xanthohumol was accomplished by Erhardt et al. in
six steps with an overall yield of 10% in 2007 (Scheme 9) [76].
The method was improved by Vogel and Heilmann et al.
[77,78] to yield also several xanthohumol derivatives occurring
as minor compounds in hop cones or as in vivo metabolites
after xanthohumol intake [77]. To date, xanthohumol in vivo
metabolites have not been investigated regarding their anti-
angiogenic activity.
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Scheme 10: Synthesis of genistein 60. Reagents and conditions: (a) 4-hydroxyphenylacetonitrile, anhydrous HCl, ZnCl2·Et2O, then aq HCl, heating or
4-hydroxyphenylacetic acid, BF3·Et2O, 120 °C; (b) BF3·Et2O, DMF, MeSO2Cl, 100 °C, 2 h.
Genistein
Genistein (60) is an isoflavone extracted from soybeans
(Glycine max (L.) MERR, Fabaceae). It is present as the 7-O-
glycoside genistein in the plant; however, during the processing
of soya products, a significant amount of the aglycone genis-
tein is released. Genistein was originally described as an exclu-
sive inhibitor of tyrosine-specific protein kinases [79]. These
kinases are responsible for the tyrosine-specific protein phos-
phorylation, which is required for the regulation of cell func-
tions, including cell proliferation and cell transformation. Later,
genistein was also found to act as an oestrogen receptor agonist
[80]. The anti-angiogenic potential of genistein was first
reported by Fotsis et al. in 1993 [81]. Then, further studies
showed that genistein inhibited angiogenic processes in various
in vitro and in vivo models [82,83]. The typical synthesis of
genistein starts from 1,3,5-trihydroxybenzene (29, Scheme 10)
[84]. After the Houben–Hoesch reaction or Friedel–Crafts
acylation, the cyclization of the resulting hydroxyketone 59 in
the presence of BF3·Et2O gave genistein (60) in good yield.
In the Friedel–Crafts acylation, BF3·Et2O was used as the cata-
lyst and solvent. The following formation of the pyrone was
also catalyzed by BF3·Et2O, and a convenient one-pot synthesis
of 60 was achieved without isolation of 59 [85].
Fisetin and quercetin
The flavonoids fisetin (67) and quercetin (68) belong to the
flavonol subgroup that exhibit a double bond between C-2/C-3
and a hydroxy group at C-3. Flavonols are the most abundant
flavonoid subtype in plants and commonly occur as glycosides.
Nevertheless, pharmacological testing was historically concen-
trated on the investigation of the aglycones. Although this has
been often criticized, it is most likely an important aspect with
regard to flavonoid metabolism. It has been shown that the
flavonoid glycosides are not absorbed after oral intake but are
cleaved by lactase-phlorizin hydrolase and absorbed as the
corresponding aglycone. The aglycone passes through the cell
membrane by passive diffusion and undergoes phase-II metabo-
lism in enterocytes and the liver, leading to glucuronides as the
main metabolites. However, a release of the aglycones from the
glucuronides in tissues or cells with β-glucuronidase activity is
possible [86].
Fisetin can be found in many fruits such as strawberries and
apples (Malus spec. MILL., Rosaceae) as well as in vegetables
such as onions (Allium cepa L., Amaryllidaceae, subfamily
Allioideae former family Alliaceae). It shows anticancer
activity in various cancer models. For example, it can inhibit
androgen receptor signaling and tumor growth in athymic nude
mice [87], it can cause apoptosis and cell-cycle arrest in human
prostate cancer LNCaP cells [88] and in HCT-116 human colon
cancer cells, and it can induce apoptosis associated with an
increased level of p53 [89]. Singh and Bhat et al. [90]
tested its anti-angiogenic activity for the first time. Their study
revealed that fisetin (10–50 µM) strongly inhibits the growth,
proliferation and cell-cycle progression in HUVECs by down-
regulating the expression of VEGF and eNOS. Another recent
study [91] also demonstrated that fisetin inhibits MMPs and
reduces tumor-cell invasiveness and endothelial cell tube for-
mation.
Together with kaempferol, quercetin is the most abundant agly-
cone in flavonol glycosides. Quercetin glycosides occur in
higher concentrations in onions, red wine, and green tea and in
various medicinal plants [92]. In a number of early studies
[93,94], quercetin showed a strong ability to inhibit tumor
growth in vivo. Quercetin suppresses angiogenesis through
multiple mechanisms such as inhibition of COX-2 and lipoxy-
genase (LOX)-5, interference with the EGF receptor, the human
epidermal growth factor receptor-2 (HER-2) intracellular
signaling pathway, and the NF-κB nuclear transcription protein
[7,8]. Chen et al. [95] reported that quercetin inhibited the
proliferation of choroids retina endothelial cells and the migra-
tion and tube formation of RA/6A cells were also significantly
inhibited by quercetin in a dose-dependent manner. In some cell
types, quercetin is also able to activate the angiogenic pathway
by inhibiting HIF-prolyl hydroxylase [96]. Zhao et al. [97]
investigated the anti-angiogenic activity of quercetin in trans-
genic zebrafish embryos and in HUVECs. The formation of
intersegmental vessels was disrupted in the zebrafish model. In
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Scheme 11: Synthesis of fisetin (67) and quercetin (68). Reagents and conditions: (a) 3,4-dimethoxybenzaldehyde, KOH, DMF, 0 °C; (b) BiCO3,
AcOH, 2-ethoxyethanol, Δ; (c) BBr3, DCM, −78 °C → rt.
HUVECs, quercetin inhibited cell viability, the expression of
VEGF-2 and tube formation in a dose-dependent manner.
The synthesis of fisetin and quercetin can be achieved by two
different methods. The first choice for synthesizing fisetin and
quecetin is by the Allan–Robinson reaction [98]. However, this
reaction has some drawbacks such as harsh experimental condi-
tions and the necessity of selective protection and deprotection
of the hydroxy groups with benzyl and/or benzoyl groups. An
alternative method is the Algar–Flynn–Oyamada (AFO) reac-
tion [99]. This allows the direct synthesis of flavone-3-ols,
although the yields vary depending on the substrates used.
Simpson et al. [100] improved the reaction conditions of AFO
in order to synthesize the flavonol rhamnocitrin by using
bismuth carbonate and acetic acid. This increased the yields to
71% and the overall yields to 52% over two steps. According to
this, a synthesis of fisetin and quercetin with methyl-protected




(69, Figure 8) is a prenylated flavanone isolated from Sophora
flavescens by Wang and Yuan et al. in 2013 [101]. It displays
inhibitory effects on cell proliferation, cell migration, cell adhe-
sion and tube formation in the human umbilical vein endothe-
lial cell line ECV304. These four steps are important in angio-
genesis. A mechanistic study showed that compound 69 is
able to downregulate ROS levels and VEGF expression in a
dose-dependent manner, and to arrest cell cycle in the G0/G1
phase.
Figure 8: Structure of (2S)-7,2’,4’-trihydroxy-5-methoxy-8-(dimethyl-
allyl)flavanone (69).
Conclusion
As pathological angiogenic processes are believed to contribute
to several diseases, compounds with anti-angiogenic activity
have been intensively investigated. In addition to antibodies,
several low molecular weight compounds have also been chem-
ically and pharmacologically characterized and among them,
several secondary metabolites of natural origin. In anti-angio-
genic strategies, natural products with phenolic substructures or
belonging to polyphenols are of special importance as they
occur in several food and medicinal plants important for human
diet and health. Despite the fact that phenolic compounds often
show specific interactions in biological systems, most of them
are pleiotropic substances with effects on different cellular
networks or targets. Several natural phenolic angiogenic inhibi-
tors such as curcumin (3), epigallocatechin-3-O-gallate (52) and
xanthohumol (58) also showed remarkable chemopreventive
activity. However, the stability, availability from natural
sources and bioactivity of the natural compounds are typically
limited. Thus far, no example of very strong anti-angiogenic
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activity in the nanomolar range has been found. Thus, synthetic
approaches for the production, diversification and optimization
are required. The modification of the polyphenol structures to
improve their stability and bioactivity and further enhance their
anti-angiogenic activity is the main goal of current research in
the field. Analogs of the natural phenols with improved drug
properties may be promising candidates for future oncology
treatment.
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